<code id='73C71445F1'></code><style id='73C71445F1'></style>
    • <acronym id='73C71445F1'></acronym>
      <center id='73C71445F1'><center id='73C71445F1'><tfoot id='73C71445F1'></tfoot></center><abbr id='73C71445F1'><dir id='73C71445F1'><tfoot id='73C71445F1'></tfoot><noframes id='73C71445F1'>

    • <optgroup id='73C71445F1'><strike id='73C71445F1'><sup id='73C71445F1'></sup></strike><code id='73C71445F1'></code></optgroup>
        1. <b id='73C71445F1'><label id='73C71445F1'><select id='73C71445F1'><dt id='73C71445F1'><span id='73C71445F1'></span></dt></select></label></b><u id='73C71445F1'></u>
          <i id='73C71445F1'><strike id='73C71445F1'><tt id='73C71445F1'><pre id='73C71445F1'></pre></tt></strike></i>

          Home / entertainment / comprehensive

          comprehensive


          comprehensive

          author:explore    Page View:69
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In